Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026

Same author

Challenges of chimerism analysis using Next-Generation sequencing in a patient with complex chromosomal alterations.

Human immunology·2026

Same author

Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.

Blood advances·2026

Same author

A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.

Blood·2026

Same author

Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study.

JMIR cancer·2026

Same author

Unlocking nature's potential: Soursop in the battle against resistant acute myeloid leukemia.

Biochemistry and biophysics reports·2025

Same journal

BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance.

Current hematologic malignancy reports·2026

Same journal

Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.

Current hematologic malignancy reports·2026

Same journal

Germline DDX41 Variants: Current Understanding and Future Directions.

Current hematologic malignancy reports·2026

Same journal

Clonal Signatures of Telomere Biology Disorders.

Current hematologic malignancy reports·2026

Same journal

Molecular Pathogenesis and Targeted Therapies for Myeloproliferative Hypereosinophilic Neoplasms.

Current hematologic malignancy reports·2026

Same journal

The Intricate Dance Between Inflammation and Myeloproliferative Neoplasms: From Origins to Outcomes.

Current hematologic malignancy reports·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 7, 2026

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

Clinical Studies in Hematologic Microtransplantation.

Kevin A David¹, Dennis Cooper¹, Roger Strair²

¹Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ, 08901, USA.

Current Hematologic Malignancy Reports

|February 24, 2017

Summary

This summary is machine-generated.

Allogeneic stem cell transplants can fight tumors without lasting donor cell engraftment, a phenomenon called microtransplantation. Recent acute myelogenous leukemia studies show microtransplantation is effective, paving the way for new cancer treatments.

Keywords:

Acute myelogenous leukemia Graft-versus-tumor Microtransplantation Stem cell transplantation

More Related Videos

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

Related Experiment Videos

Last Updated: Mar 7, 2026

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

Area of Science:

Oncology
Immunology
Hematology

Background:

Allogeneic hematopoietic stem cell transplantation (HSCT) relies on donor cell engraftment and graft-versus-tumor (GVT) effects for anti-tumor activity.
Pre-clinical and clinical evidence suggests anti-tumor responses can occur without sustained donor cell engraftment, a state termed 'microtransplantation'.

Purpose of the Study:

To review studies supporting the concept of microtransplantation.
To highlight recent acute myelogenous leukemia (AML) studies demonstrating the efficacy of microtransplantation.
To establish a foundation for further research into microtransplantation mechanisms and clinical development.

Main Methods:

Review of key pre-clinical and clinical studies on microtransplantation.
Emphasis on recent large-scale studies in acute myelogenous leukemia (AML) patients.
Analysis of factors influencing engraftment and donor chimerism in relation to anti-tumor effects.

Main Results:

Microtransplantation, characterized by tumor response with minimal or no donor cell persistence, is a viable therapeutic concept.
Recent AML studies provide the first clinical evidence for the efficacy of microtransplantation as a treatment strategy.
The degree of donor chimerism required for anti-tumor effects in microtransplantation remains an area for further investigation.

Conclusions:

Microtransplantation represents a promising therapeutic strategy in oncology, particularly for hematological malignancies like AML.
Further pre-clinical and clinical research is crucial to elucidate the underlying mechanisms of microtransplantation.
Understanding microtransplantation will guide the refinement and development of this treatment modality for broader clinical application.